MSD and Kelun-Biotech announced that China's NMPA has granted priority review to two new indication applications for sac-TMT, a drug licensed by MSD outside Greater China. This regulatory progress for sac-TMT in NSCLC and TNBC could significantly expand its market potential and accelerate its availability in China, benefiting both companies.
MSD (Merck & Co., Inc.) and Kelun-Biotech announced that China's National Medical Products Administration (NMPA) has accepted two new indication applications for sac-TMT for priority review. These applications are for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) and recurrent or metastatic triple-negative breast cancer (TNBC) in combination with pembrolizumab. This is a significant development following a 2022 licensing agreement where MSD secured exclusive rights to develop and commercialize sac-TMT outside of Greater China. The priority review status suggests an accelerated path to potential approval, which could significantly expand the market for sac-TMT and generate substantial revenue for MSD in the long term, especially given the large patient populations in China for these cancers. For Kelun-Biotech, it validates their drug development capabilities and strengthens their partnership with a global pharmaceutical giant. Traders should see this as a positive catalyst for MRK, indicating potential future revenue streams and market expansion, while also benefiting Kelun-Biotech.